Precision BioSciences (NASDAQ:DTIL) Releases Quarterly Earnings Results, Misses Estimates By $0.09 EPS

Key Points

• Precision BioSciences reported Q results of ($0.75) EPS, missing the consensus by $0.09 and showing a deeply negative profitability profile with a return on equity of -122.6% and a net margin of -133.45%.
• The company posted revenue of $10.84 million versus expectations of $4.05 million, and shares rose about 4.8% to open at $7.63, reflecting a market cap near $197 million and a 52-week range of $3.53–$8.82.
• Insiders (including the CEO and CFO) sold a total of 33,633 shares in the last three months (~$129k), while institutional ownership is ~38% and analysts maintain a mixed view with a consensus rating of Moderate Buy and an average target price of $36.33.

Precision BioSciences (NASDAQ:DTIL - Get Free Report) posted its quarterly earnings results on Tuesday. The company reported ($0.75) EPS for the quarter, missing the consensus estimate of ($0.66) by ($0.09), FiscalAI reports. Precision BioSciences had a negative return on equity of 122.60% and a negative net margin of 133.45%.The company had revenue of $10.84 million for the quarter, compared to analysts' expectations of $4.05 million.

Precision BioSciences Stock Up 4.8%

Shares of NASDAQ:DTIL opened at $7.63 on Tuesday. The company has a debt-to-equity ratio of 0.24, a current ratio of 13.32 and a quick ratio of 13.32. The firm has a market capitalization of $196.85 million, a PE ratio of -1.49 and a beta of 1.31. The firm's 50-day moving average is $6.02 and its two-hundred day moving average is $5.36. Precision BioSciences has a 1 year low of $3.53 and a 1 year high of $8.82.

Insider Transactions at Precision BioSciences

In other news, CFO John Alexander Kelly sold 8,149 shares of the business's stock in a transaction dated Wednesday, February 18th. The stock was sold at an average price of $3.84, for a total transaction of $31,292.16. Following the completion of the transaction, the chief financial officer directly owned 125,883 shares of the company's stock, valued at approximately $483,390.72. The trade was a 6.08% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CEO Michael Amoroso sold 20,559 shares of the business's stock in a transaction dated Wednesday, February 18th. The stock was sold at an average price of $3.84, for a total value of $78,946.56. Following the transaction, the chief executive officer directly owned 243,392 shares of the company's stock, valued at approximately $934,625.28. This represents a 7.79% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders have sold 33,633 shares of company stock valued at $129,151. Corporate insiders own 2.70% of the company's stock.

Hedge Funds Weigh In On Precision BioSciences

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. XTX Topco Ltd acquired a new position in shares of Precision BioSciences during the fourth quarter worth about $149,000. Sphera Funds Management LTD. acquired a new position in shares of Precision BioSciences during the fourth quarter worth about $1,648,000. Quadrature Capital Ltd grew its position in shares of Precision BioSciences by 344.7% during the fourth quarter. Quadrature Capital Ltd now owns 62,129 shares of the company's stock worth $258,000 after buying an additional 48,158 shares in the last quarter. Occudo Quantitative Strategies LP acquired a new position in shares of Precision BioSciences during the fourth quarter worth about $52,000. Finally, Engineers Gate Manager LP acquired a new position in shares of Precision BioSciences during the fourth quarter worth about $43,000. 37.99% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several research analysts have recently commented on DTIL shares. Wall Street Zen upgraded Precision BioSciences from a "sell" rating to a "hold" rating in a report on Saturday, March 14th. JonesTrading reiterated a "buy" rating and set a $30.00 price target on shares of Precision BioSciences in a report on Friday, April 17th. Finally, Jefferies Financial Group reiterated a "buy" rating and set a $19.00 price target on shares of Precision BioSciences in a report on Friday, March 13th. Three analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average target price of $36.33.

About Precision BioSciences

Precision BioSciences is a clinical‐stage genome editing company that leverages its proprietary ARCUS platform to develop targeted gene therapies. ARCUS, an engineered nuclease derived from a naturally occurring enzyme, enables precise DNA modifications for both in vivo and ex vivo applications. The company's pipeline spans genetic diseases—including rare monogenic disorders—and immuno‐oncology, where it is advancing allogeneic cell therapy candidates designed to address hematologic malignancies and solid tumors.

Founded in 2006 as a spin‐out from research at the University of North Carolina, Precision BioSciences is headquartered in Durham, North Carolina, with additional research and manufacturing capabilities located in the Research Triangle Park area.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.